Diligence memo · auto-generated · as of July 2, 2026
Promedix, Inc.
Promedix, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Promedix, Inc. operates in Biotechnology, based in PORTLAND.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Promedix, Inc. has raised $923K in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $310K on 2022-10-17.
Most recent recorded round closed around 2024-12-02.
Valuation (modeled)modeled
Provath models Promedix, Inc. at approximately $711K (range $107K–$2.1M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.22× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 19 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 17% of Biotechnology peers (4293 compared).
Modeled value ranks above 2% of those peers.
Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.